JP2020532969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532969A5 JP2020532969A5 JP2020511383A JP2020511383A JP2020532969A5 JP 2020532969 A5 JP2020532969 A5 JP 2020532969A5 JP 2020511383 A JP2020511383 A JP 2020511383A JP 2020511383 A JP2020511383 A JP 2020511383A JP 2020532969 A5 JP2020532969 A5 JP 2020532969A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- cell
- car
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 22
- 210000002865 immune cell Anatomy 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 125000006850 spacer group Chemical group 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 108091008928 CXC chemokine receptors Proteins 0.000 claims 1
- 102000054900 CXCR Receptors Human genes 0.000 claims 1
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003306 cell dissemination Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187554.5 | 2017-08-23 | ||
| EP17187554 | 2017-08-23 | ||
| PCT/EP2018/072750 WO2019038368A1 (en) | 2017-08-23 | 2018-08-23 | CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532969A JP2020532969A (ja) | 2020-11-19 |
| JP2020532969A5 true JP2020532969A5 (https=) | 2021-09-30 |
| JP7395465B2 JP7395465B2 (ja) | 2023-12-11 |
Family
ID=59713849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511383A Active JP7395465B2 (ja) | 2017-08-23 | 2018-08-23 | キメラ抗原受容体と、ｃｘｃｒ５に結合するｃａｒ－ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11643468B2 (https=) |
| EP (1) | EP3672989A1 (https=) |
| JP (1) | JP7395465B2 (https=) |
| KR (1) | KR102804751B1 (https=) |
| CN (1) | CN111094349B (https=) |
| AU (2) | AU2018321134B2 (https=) |
| CA (1) | CA3072859A1 (https=) |
| SG (1) | SG11202001011XA (https=) |
| WO (1) | WO2019038368A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526340A (ja) | 2019-03-25 | 2022-05-24 | マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト | Ｅｂａｇ９を阻害することによる細胞溶解性ｔ細胞の活性の増強 |
| US20220186232A1 (en) * | 2019-03-26 | 2022-06-16 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed tregs expressing cars |
| AU2020393334A1 (en) * | 2019-11-25 | 2022-06-16 | Kyoto University | T-cell master cell bank |
| JP7789342B2 (ja) * | 2021-04-30 | 2025-12-22 | 国立大学法人東海国立大学機構 | キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法 |
| CN113549599B (zh) * | 2021-07-20 | 2024-02-20 | 徐州医科大学 | 靶向cxcr5阳性细胞的car-t细胞、核酸、载体、慢病毒及car-t细胞的应用 |
| CN119371550A (zh) * | 2023-08-10 | 2025-01-28 | 深圳市三启生物技术有限公司 | 含有gprc5d抗体的嵌合抗原受体及其应用 |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| DE4332256C1 (de) * | 1993-09-22 | 1995-03-09 | Lipp Martin Dr Dr Habil | Monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| EP1079688A1 (en) | 1998-05-26 | 2001-03-07 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| CN111909273B (zh) * | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| CA2945320A1 (en) * | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| AU2015305850A1 (en) * | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR5 |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| JP7030811B2 (ja) * | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| JP7066714B2 (ja) * | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
-
2018
- 2018-08-23 SG SG11202001011XA patent/SG11202001011XA/en unknown
- 2018-08-23 CN CN201880056053.1A patent/CN111094349B/zh active Active
- 2018-08-23 EP EP18759305.8A patent/EP3672989A1/en active Pending
- 2018-08-23 US US16/641,181 patent/US11643468B2/en active Active
- 2018-08-23 CA CA3072859A patent/CA3072859A1/en active Pending
- 2018-08-23 KR KR1020207008094A patent/KR102804751B1/ko active Active
- 2018-08-23 AU AU2018321134A patent/AU2018321134B2/en active Active
- 2018-08-23 WO PCT/EP2018/072750 patent/WO2019038368A1/en not_active Ceased
- 2018-08-23 JP JP2020511383A patent/JP7395465B2/ja active Active
-
2025
- 2025-06-14 AU AU2025204455A patent/AU2025204455A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532969A5 (https=) | ||
| JP2019527537A5 (https=) | ||
| JP6633081B2 (ja) | 細胞 | |
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| Boettcher et al. | Development of CAR T cell therapy in children—A comprehensive overview | |
| CN109843928B (zh) | 抗O-乙酰化的GD2神经节苷脂（OAcGD2）的人源化抗体 | |
| AU2023201386A1 (en) | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking | |
| JP2017527275A5 (https=) | ||
| JP2020530989A5 (https=) | ||
| JP2019193652A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| JP2018508215A5 (https=) | ||
| JPWO2019173324A5 (https=) | ||
| JP2017522893A5 (https=) | ||
| JP2017500869A5 (https=) | ||
| JP2017519502A5 (https=) | ||
| JP2018537076A5 (https=) | ||
| JP2018528776A5 (https=) | ||
| JP2024521405A (ja) | Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質 | |
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| CN114805573B (zh) | 抗tim3单克隆抗体和嵌合抗原受体 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| JPWO2023154890A5 (https=) |